Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD Tailored Treatment for Young Patients With High-risk CLL
NCT05478512Phase 2Active, not recruiting
- Sponsor
- GIMEMA
- Start
- Jul 2023
- Primary completion
- May 2026
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, obinutuzumab, zanubrutinib in chronic lymphocytic leukemia (CLL), sponsored by GIMEMA. Started Jul 2023; status: active, not recruiting.
02
Drugs
venetoclaxobinutuzumabzanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05478512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478512.